
## Phospho-Stat4 (Tyr693) (F6) rabbit mAb

www.abwizbio.com Support: info@abwizbio.com Order: sales@abwizbio.com


Catalog: #2281 Store at: -20°C

For Research Use Only. Not For Use In Diagnostic Procedures.


<b>Applications</b> Flow Cytometry	<b>Detection</b> Anti-Rabbit IgG	<b>Clonality</b> Monoclonal	<b>Isotype</b> Rabbit IgGk	
	·	, ionecional	Nasan igen	
Format:	Unconjugated			
Cross Reactivity:	Predicted to work with mouse, rat and other homologues.			
Formulation:	1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA			
Preparation:	Protein A+G			
Reactivity:	Human,Mouse			
Recommended Usage:	$1\mu g/mL$ – $0.001\mu g/mL$ . It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.			
Immunogen:	A synthetic phospho-peptide corresponding to residues surrounding Tyr693 of human phospho Stat4			
Description:	In response to IL-12 binding, the IL-12 receptor activates the Jak kinases, which phosphorylate tyrosine residues of IL-12R $\beta$ 2. These phosphorylated receptors recruit Stat4 through its SH2 domain, whereupon Stat4 is phosphorylated at Tyr693 in its C-terminal transactivation domain. Phosphorylation promotes Stat4 homodimerization and translocation to the nucleus, where it promotes gene transcription. The N-terminal domain of Stat4 appears to be required for maximal stabilization and for the binding of Stat4 dimers to lower-affinity DNA binding sites. Stat4-deficient mice have demonstrated that this gene is required to both promote Th1 development and inhibit Th2 differentiation due to disabling IL-12 receptor-mediated responses.			
References:	Kaplan MH, Sun Y, Hoey T, and Grusby MJ. (1996) Nature. 382: 174-177. Chang H, Zhang S, Oldham I, Naeger L, Hoey T, and Kaplan MH. (2003) Journal of Biological Chemistry. 278: 32471-32477.			




Flow cytometric analysis of K562 cells unstained and treated with imatinib as negative control (blue) or treated with imatinib and stained (red) or treated with IFN $\alpha$  + IL-4 + pervanadate and stained (green) using Phospho-Stat4 (Tyr693) antibody Stat4Y693-F6 at 0.01 µg/mL. Cat #2281.



Flow cytometric analysis of NIH3T3 cells secondary antibody only negative control (blue) or treated with imatinib (red) or with pervanadate (green) using Phospho-Stat4 (Tyr693) antibody Stat4Y693-F6 at 0.1  $\mu$ g/mL. Cat #2281.



Flow cytometric analysis of K562 cells secondary antibody only negative control (blue) or treated with imatinib (red) or with pervanadate (green) using 0.01 ug/mL of Phospho-Stat4 (Tyr693) antibody Stat4Y693-F6 Cat. #2281 or Company C at 0.1 ug/mL (manufacturer's recommended concentration).



SampleID	Treatment	Peptide Block	Median : BL1-A
F6	IFN	Non-phos.	6432
F6	Ctrl	Non-phos.	3583
F6	IFN	Phospho.	1119
F6	Ctrl	Phospho.	665
F6	IFN	-	6146
F6	Ctrl	-	3481
2' only	Ctrl	-	551

Peptide blocking flow cytometric analysis of K562 cells secondary antibody only negative control (light blue) or untreated (grey) or IFN $\alpha$  + IL-4 + pervanadate-treated (orange) using 0.1 µg/mL isotype control Cat. #2141 or untreated (red) or treated (green) or untreated and blocked with phospho-peptide (black) or treated and blocked with phospho peptide (gold) or untreated and blocked with non-phospho peptide (dark blue) or treated and blocked with non-phospho peptide (purple) using Phospho-Stat4 (Tyr693) antibody Stat4Y693-F6 at 0.1 µg/mL. Cat. #2281.